SUPERNUS PHARMACEUTICALS, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $46.64 per share for the 3-month period ending 2011-12-31, per its 10-K filed 2013-03-15.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2013-03-15
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-12-31 was $46.64.
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-09-30 was $0.26.
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-06-30 was $0.98.
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-03-31 was -$0.84.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month |
|---|---|
| 2011-12-31 | $46.64 10-K · filed 2013-03-15 |
| 2011-09-30 | $0.26 10-K · filed 2013-03-15 |
| 2011-06-30 | $0.98 10-K · filed 2013-03-15 |
| 2011-03-31 | -$0.84 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |